In the present study, we evaluated how a pharmacologically induced phenotype shift in dystrophic skeletal muscle would affect subsequent intracellular signaling in response to a complementary, adaptive physiological stimulus. mdx mice were treated with the AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR; 500 mg·kg Ϫ1 ·day Ϫ1 ) for 30 days, and then one-half of the animals were subjected to a bout of treadmill running to induce acute AMPK and p38 MAPK signaling. The mRNA levels of phenotypic modifiers, including peroxisome proliferator-activated receptor-␦ (PPAR␦), PPAR␥ coactivator-1␣ (PGC-1␣), receptor interacting protein 140 (RIP 140), and silent information regulator two ortholog 1 (SIRT1) were assessed in skeletal muscle, as well as the expression of the protein arginine methyltransferase genes PRMT1 and CARM1. We found unique AMPK and p38 phosphorylation and expression signatures between dystrophic and healthy muscle. In dystrophic skeletal muscle, treadmill running induced PPAR␦, PGC-1␣, and SIRT1 mRNAs, three molecules that promote the slow, oxidative myogenic program. In the mdx animals that received the chronic AICAR treatment, running-elicited AMPK and p38 phosphorylation was attenuated compared with vehicletreated mice. Similarly, acute stress-evoked expression of PPAR␦, PGC-1␣, and SIRT1 was also blunted by chronic pharmacological AMPK stimulation. Skeletal muscle PRMT1 and CARM1 protein contents were higher in mdx mice compared with wild-type littermates. The acute running-evoked induction of PRMT1 and CARM1 mRNAs was also attenuated by the AICAR treatment. Our data demonstrate that prior pharmacological conditioning is a salient determinant in how dystrophic muscle adapts to subsequent complementary, acute physiological stress stimuli. These results provide insight into possible therapeutic applications of synthetic agonists in neuromuscular diseases, such as during chronic administration to Duchenne muscular dystrophy patients.
5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside; p38 mitogen-activated protein kinase; mdx mice; peroxisome proliferatoractivated receptor-␥ coactivator-1␣; protein arginine methyltransferases SKELETAL MUSCLE PHENOTYPE is remarkably plastic and can change rapidly following the introduction of a potent stimulus. For example, chronic muscle use can cause a phenotypic shift from a fast, glycolytic muscle type to a functionally slower, more oxidative muscle, whereas disuse elicits the opposite effect (56) . In healthy muscle, initiation of the slow, oxidative myogenic program is triggered via the chronic activation of numerous intracellular factors, such as protein phosphatases, kinases, transcriptional mediators, and DNA-binding molecules. Specifically, activation of calcineurin/NFAT (nuclear factor of activated T cells) signaling triggers a shift in muscle fiber type from fast glycolytic to slow oxidative (17, 58) . Habitual stimulation of AMP-activated protein kinase (AMPK) and mitogen-activated protein kinase (MAPK) p38 also results in phenotypic remodeling toward a slower, more oxidative skeletal muscle (1, 5, 15, 22, 28, 37, 57, 73) . Furthermore, the transcriptional coactivator peroxisome proliferator-activated receptor-␥ (PPAR␥) coactivator-1␣ (PGC-1␣) and the histone deacetylase silent information regulator two ortholog 1 (SIRT1) are components of potent phenotype-shifting signaling cascades (37, 70) , whereas the transcription factor PPAR␤/␦ (PPAR␦) is also capable of evoking the slow, oxidative myogenic program (21) . In contrast, the transcriptional corepressor receptor interacting protein 140 (RIP 140) appears to promote the fast, glycolytic myogenic program and/or repress the slow, oxidative phenotype (59) . Thus numerous signaling pathways regulate, or have the potential to mediate, phenotypic plasticity in healthy skeletal muscle.
In contrast to what has been described regarding the molecular mechanisms that mediate muscle remodeling in healthy tissue, relatively little has been documented about the signaling networks regulating the same processes in pathophysiological conditions. This is unfortunate, since studying these may reveal novel possibilities for therapeutic lifestyle and/or pharmacological interventions. Indeed, it has been known for ϳ20 yr that slow, oxidative myofibers in both Duchenne muscular dystrophy (DMD) patients and the dystrophin-negative mdx mouse model of muscular dystrophy show significantly reduced damage compared with faster, more glycolytic muscle fibers (47, 72) . Based on our work (2, 13, 14, 25, 40, 45) and that of others (26, 63) , the overarching hypothesis in our laboratory has been that evocation of the slow, oxidative skeletal muscle phenotype attenuates the dystrophic pathology and represents a physiologically relevant therapeutic possibility.
In dystrophic skeletal muscle, a small but growing number of intracellular signaling molecules are known to elicit the slow, oxidative myogenic program, such as calcineurin, NFAT, and PGC-1␣ (2, 13, 14, 26, 63) , whereas the role of other phenotype-shifting proteins, including p38, SIRT1, and RIP 140, remains largely undefined. We have recently demonstrated that stimulation of PPAR␦ and AMPK signaling using the synthetic agonists GW501516 and 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR), respectively, was able to evoke the slow myogenic program and rescue muscle function in mdx animals (40, 45) . However, it is unknown how these pharmacologically induced phenotype shifts affect subsequent intracellular signaling and, ultimately, how dystrophic skeletal muscle will respond to further adaptive physiological stimuli. Thus the purpose of this investigation was to evaluate the adaptive signaling response in chronically AICAR-treated mdx animals subsequent to a single bout of acute contractile activity, a stress stimulus well known to induce AMPK and p38 signaling (24, 37, 39, 52, 74) . Furthermore, this study aimed to shed new light on the ability of mdx mouse muscle to adapt over time to a contextually novel pharmacological intervention, which has relevance for potential future therapeutic applications of AMPK agonists, such as during potentially long-term clinical use in DMD patients.
METHODS
In vivo AICAR treatment. Experiments were conducted after approval by the University of Ottawa Animal Care Committee in accordance with Canadian Council of Animal Care guidelines. AICAR (TRC, Toronto, Canada) was dissolved in sterile saline at 50 mg/ml immediately before daily treatments. Five-to seven-week-old mdx mice (C57BL/10ScSn-Dmd mdx /J; Jackson Laboratory, Bar Harbor, ME) were treated with 500 mg/kg AICAR or vehicle daily by subcutaneous interscapular injections for 30 days. This AICAR dosage and method of delivery was based on previous studies (3, 10, 22, 28) .
Acute treadmill running stimulus. This experimental protocol was executed in best accordance with putative standard operating procedures (available at http://www.treat-nmd.eu/research/preclinical/ dmd-SOPs; SOP ID# DMD_M.2.1.003), as well as with standards outlined by Booth et al. (6) . On the 30th day of AICAR treatment, one mouse from each of the three experimental groups, vehicle (saline)-treated wild type mice (WT ϩ Veh), vehicle-treated mdx mice (mdx ϩ Veh), and AICAR-treated mdx mice (mdx ϩ AICAR), was placed on a custom-engineered, motor-driven, four-lane rodent treadmill (67) . The three mice (triad) then walked at 5 m/min for 10 min at a 15-deg decline. This acclimatization procedure was done one triad at a time. On the following day, groups of triads were subjected to a running protocol of progressive intensity that comprised running at a 15-deg decline for 5-min blocks at speeds of 5, 10, 15, 20, and finally 25 m/min until an inability to continue exercise was determined. Triads were encouraged to run using mechanical prodding (e.g., tapping of the tail, brushing of the back; Ref. 32) with a 10-ml serological pipette (Diamed, Mississauga, Canada). Mice ran until they were unable to stay away from the back wall of the treadmill despite concerted stimulation (67) . Immediately after the end of the run, the mouse was removed from the treadmill and the inability to continue exercise (i.e., fatigue) was verified by an attenuation of the righting reflex when the animal was placed on its back (6, 18) . Running encouragement and identification of the mouse's inability to continue exercise were determined in an experimenter-blinded fashion, where the experimental treatment of each animal in each triad was unknown to the attending scientist. After a 3-h recovery period following the running stimulus, mice were euthanized and the tibialis anterior (TA) muscles were harvested and snap frozen in liquid nitrogen for subsequent protein and mRNA analyses.
Protein analysis. Frozen TA muscle sections were ground to a powder with a porcelain mortar and pestle on dry ice. Muscle samples were suspended in a modified RIPA buffer (Sigma-Aldrich, Oakville, Canada) supplemented with cOmplete Mini Protease Inhibitor Cocktail and PhosSTOP (Roche, Laval, Canada), mechanically homogenized, repeatedly flash freeze-thawed, and spun. The protein concentrations of the supernates were determined using Bradford's method (9) with bovine serum albumin (BSA) as the standard. Proteins extracted from the muscle homogenates were resolved by SDS-PAGE (10% polyacrylamide) and subsequently electroblotted to nitrocellulose membranes (Bio-Rad, Mississauga, Canada). After transfer, membranes were stained with Ponceau S (Sigma-Aldrich) to confirm equal loading between lanes. , PRMT1 (Sigma-Aldrich P1620), CARM1 (Bethyl A300 -421A, Montgomery, TX), or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Advanced ImmunoChemical 2-RGM2 6C5, Long Beach, CA) overnight at 4°C with gentle rocking. After three 5-min washes with TBST, blots were incubated at room temperature (1 h) with the appropriate secondary antibody coupled to horseradish peroxidase. Blots were then washed again three times for 5 min with TBST, followed by visualization with enhanced chemiluminescence (Western Lightning ECL; PerkinElmer, Woodbridge, Canada). Films (CL-X Posure; Thermo Scientific, Rockford, IL) were then scanned and analyzed using ImageJ (NIH, Bethesda, MD).
mRNA analysis. Total RNA was isolated from frozen TA muscle powders using TRIzol reagent (Invitrogen, Carlsbad, CA) and treated with DNase I (Fermentas, Burlington, Canada) to eliminate possible DNA contamination. Endogenous mRNAs were measured using realtime quantitative RT-PCR (Agilent Tech, Mississauga, Canada), and the ⌬C T method was used to quantify target gene expression relative to the level of GAPDH as noted previously (45) .
Target gene primers were designed using Primer3 software. Forward and reverse primers for target genes were as follows: PPAR␦ forward primer (FP) 5=-GCCTCCATCGTCAACAAAGA, reverse primer (RP) 5=-TCTACCTGGGGCACATTCAT; PGC-1␣ FP 5=-TACGCAGGTCGAACGAAACT, RP 5=-GAAGCAGGGTCAAAA-TCGTC; RIP 140 FP 5=-ACTTCCCGCTGCAGAAACTA, RP 5=-GCGTTTCCCAGAAGTCCATA; SIRT1 FP 5=-GATACCTTGGAG-CAGGTTGC, RP 5=-CTTTACGAACAGCTTCACAA; PRMT1 FP 5=-GCCTGCAAGTGAAGAGGAAC, RP 5=-CTCAGGACTGGTG-GAGAAGC; CARM1 FP 5=-ACCACACGGACTTCAAGGAC, RP 5=-CTCTTCACCAGGACCTCTGC; and GAPDH FP 5=-GGGTGT-GAACCACGAGAAAT, RP 5=-CCTTCCACAATGCCAAAGTT.
Statistical analysis. The data were analyzed using unpaired Student's t-tests (rest ϫ run treatments within the experimental groups, see RESULTS), one-way analysis of variance (ANOVA; for comparisons between the 3 experimental groups), and two-way factorial ANOVA (experimental group ϫ treatment) procedures, as appropriate (StatPlus, Vancouver, Canada). Bonferroni's post hoc test was used to test significant differences revealed by the ANOVAs. Statistically significant distinctions between groups represented in the graphs depicted as fold differences are computed using the raw data sets before conversion to the fold difference values. Significance was accepted at P Ͻ 0.05. Graphs depict group means Ϯ SE.
RESULTS

Effect of chronic AICAR administration on skeletal muscle
AMPK and p38 signaling in mdx mice. We previously treated mdx mice with 500 mg·kg Ϫ1 ·day Ϫ1 AICAR for a duration of 30 days and assessed the impact that this compound had on the dystrophic phenotype (40) . The AICAR dosage and time course of administration employed in that earlier study as well as in the current investigation were based on earlier works (3, 10, 22, 28) . In the current study, we first assessed AMPK and p38 signaling under basal, resting conditions in the skeletal muscle of WT ϩ Veh, mdx ϩ Veh, and mdx ϩ AICAR mice. AMPK phosphorylation, identified by a phospho-specific Thr 172 antibody, was ϳ1.4-fold greater (P Ͻ 0.05) in the TA muscle of mdx animals compared with WT mice (Fig. 1B) . In contrast, p38 MAPK phosphorylation, recognized using a phospho-specific Thr 180 /Tyr 182 antibody, was found to be 40 - 50% lower (P Ͻ 0.05) in mdx animals vs. WT mice (Fig. 1C ), similar to previous data (8) . Chronic AICAR administration had no effect on basal AMPK or p38 phosphorylation in mdx mice ( Fig. 1 , B and C). As noted on occasion in the literature (7), phosphorylated p38␥ (upper band) and p38␣ subunits (lower band) were detected by Western blot analyses (Fig. 1A) . We next established baseline conditions for the total contents of the kinases. Total AMPK protein content in the TA muscle from mdx mice was ϳ2.5-fold greater (P Ͻ 0.05) compared with WT animals (Fig. 1D) . AICAR had no influence on AMPK levels. Compared with WT ϩ Veh animals, p38 protein content was 2.5-fold greater (P Ͻ 0.05) in mdx ϩ Veh mice (Fig. 1E) . Chronic AICAR treatment in the mdx ϩ AICAR group significantly attenuated this difference between WT ϩ Veh and mdx ϩ Veh animals (Fig. 1E) .
Phosphorylation status, represented as the ratio of phosphorylated form of the kinase relative to the total protein kinase content, was assessed as previously documented (1, 39, 43) . The phosphorylation status of AMPK and p38 was 45-75% lower (P Ͻ 0.05) in mdx animals compared with WT mice (Fig. 1, F and G). Chronic AICAR treatment had no influence on phosphorylation status in mdx animals.
Acute physical activity as a stimulus for intracellular signal transduction in skeletal muscle. Acute contractile activity robustly activates numerous intracellular signaling cascades in skeletal muscle, including AMPK and p38 (24, 37, 39, 52, 74) . Therefore, a single bout of treadmill running of progressive intensity was employed to stimulate protein kinase activation in the contracting muscles of WT ϩ Veh, mdx ϩ Veh, and mdx ϩ AICAR animals. As expected (11) , mdx ϩ Veh animals ran significantly less compared with WT ϩ Veh mice, evidenced by a lower run time ( Fig. 2A) as well as a shorter run distance (Fig. 2B) until the inability to continue running was determined. The volume of running was similar to previously reported data (11) . Prior AICAR treatment in mdx mice did not affect exercise performance, indicating that pharmacological AMPK stimulation alone, in the absence of exercise training, did not improve endurance. These data contrast earlier findings (54) , which to our knowledge are from the first study to declare AICAR as a performance-enhancing drug in ϳ15 yr of research on AICAR and skeletal muscle adaptations (44, 77) . The presence of the dystrophic pathology, different treadmill protocols, or unique methodologies for the identification of an inability to continue exercise between investigations could all account for the disparity in results.
Chronic AICAR treatment attenuates acute AMPK and p38 phosphorylation. Activation of AMPK and p38 MAPK has profound downstream effects on skeletal muscle plasticity (37) . Of particular relevance is the ability of chronic AMPK and p38 stimulation to evoke the slow, oxidative myogenic program (1, 5, 15, 22, 28, 37, 57, 73) , which is known to be beneficial in ameliorating the dystrophic pathology (13, 25, 26, 40, 45, 47, 63, 72) .
In an effort to understand the effects of chronic AICAR exposure on AMPK and p38 signaling in response to an acute stress stimulus, we assessed kinase phosphorylation levels subsequent to the treadmill running protocol. The purpose of this particular experiment was to compare the kinase signaling response subsequent to one acute bout of contractile activity in the three experimental groups. AMPK activation was increased by 1.5-to 1.8-fold (P Ͻ 0.05) in response to acute physical activity (i.e., "run") in the WT ϩ Veh and mdx ϩ Veh groups, respectively, compared with animals in those groups that were not exposed to the treadmill running protocol (i.e., "rest"; Fig. 3, A and B) . In contrast, chronic AICAR administration completely ablated (P Ͻ 0.05) the running-induced increase in AMPK phosphorylation (Fig. 3C) . After AICAR treatment, AMPK phosphorylation was not significantly different between rest and run animals in the mdx ϩ AICAR group. The single bout of treadmill running did not affect the total levels of AMPK protein (Fig. 3, A-C, middle row of graphs) . This finding was to be expected considering previous reports on kinase contents in response to acute bouts of contractile activity (1, 7, 38, 39, 43, 52) . As such, the ratio of phosphorylated AMPK to total AMPK protein content reflected the levels of phosphorylated AMPK in the muscles (Fig. 3, A-C, bottom  row of graphs) .
In response to the acute running stimulus, p38 phosphorylation increased 5.7-fold (P Ͻ 0.05) compared with sedentary controls in the WT ϩ Veh group (Fig. 4A) . In the mdx ϩ Veh animals, p38 activation was augmented by 4.1-fold (P Ͻ 0.05) in the run mice compared with the rest mice (Fig. 4B) . The level of p38 phosphorylation in the mdx ϩ AICAR mice subjected to the acute running stimulus was elevated to a significantly lesser extent (P Ͻ 0.05) relative to the mdx ϩ Veh mice, only by threefold (P Ͻ 0.05) compared with their sedentary controls (Fig. 4C) . Similar to the data on AMPK (Fig. 3) , total levels of p38 protein were unchanged in response to the acute running protocol (Fig. 4 , A-C, middle row of graphs). As a result, the ratio of phosphorylated p38 to total p38 protein content reflected the levels of phosphorylated p38 in the myofibers (Fig. 4, A-C, bottom row of graphs) . Effects of acute and chronic signaling stimuli on the expression of phenotypic modifiers in dystrophic muscle. We next evaluated the mRNA expression level of a targeted suite of genes, many of which play a known role in influencing skeletal muscle phenotype (21, 37, 59, 70) . Importantly, a number of these molecules have been shown to be induced downstream of AMPK and/or p38 activation in healthy animals (1, 30, 40, 64, 65) . The experimental design employed in the current study allows for the examination of muscle gene expression during three physiological phenomena where skeletal muscle intra- Fig. 4 . Skeletal muscle p38 MAPK phosphorylation content at rest and after treadmill running. The levels of phosphorylated p38 (top row of graphs) and total p38 (middle row of graphs) and the ratio of phosphorylated to total p38 (bottom row of graphs) are shown in TA muscle extracts from WT ϩ Veh (A), mdx ϩ Veh (B), and mdx ϩ AICAR mice (C) at rest and after treadmill running. Typical Western blots are shown above the graphs. Data are expressed as the Run-induced fold increase in p38 relative to the Rest levels (n ϭ 5-7). *P Ͻ 0.05 vs. Rest. §P Ͻ 0.05 vs. Run-evoked increase observed in mdx ϩ Veh group. cellular signaling is perturbed: 1) the dystrophic pathology, 2) chronic AMPK stimulation via AICAR, and 3) acute intense treadmill running.
Skeletal muscle phenotypic plasticity can be elicited by the actions of the nuclear receptor PPAR␦, the transcriptional coactivator PGC-1␣, and corepressor RIP 140, as well as the histone deacetylase SIRT1 (21, 37, 59, 70) . Moreover, it was recently discovered that the expression level of these proteins is altered in dystrophic muscle compared with healthy tissue (40, 45) . Therefore, we measured the mRNA expression of these potent phenotype modifiers in dystrophic muscle in response to chronic AICAR exposure and acute physical activity. The levels of PPAR␦ in the muscle of Rest animals were similar across all experimental groups (Fig. 5A) . The acute running stress had no effect on PPAR␦ mRNA expression in the fast, glycolytic TA muscle of WT animals, similar to previously reported findings (61) . The running stimulus increased gene expression by ϳ2.7-fold (P Ͻ 0.05) in the mdx ϩ Veh mice. In comparison, this run-evoked elevation in PPAR␦ expression was significantly less (P Ͻ 0.05) in the mdx ϩ AICAR animals. Indeed, PPAR␦ mRNA levels in the mdx ϩ AICAR run group was only twofold (P Ͻ 0.05) greater than in the mdx ϩ AICAR rest animals.
The content of skeletal muscle PGC-1␣ mRNA was similar between the rest groups of WT ϩ Veh, mdx ϩ Veh, and mdx ϩ AICAR animals (Fig. 5B) . The acute treadmill running protocol augmented PGC-1␣ expression by 1.4-and 2-fold (P Ͻ 0.05) in the WT ϩ Veh and mdx ϩ Veh groups, respectively. However, the run-induced increase in PGC-1␣ level in mdx mice was completely ablated (P Ͻ 0.05) in the animals that received prior chronic AICAR treatment.
RIP 140 mRNA expression was significantly greater in mdx animals compared with WT mice in resting skeletal muscle (Fig. 5C ). The level of RIP 140 was 20% lower in mdx ϩ AICAR animals vs. mdx ϩ Veh mice; however, this value did not meet statistical significance (P ϭ 0.09). Acute treadmill running increased RIP 140 expression by 1.5-, 2.3-, and 2.1-fold (P Ͻ 0.05) in WT ϩ Veh, mdx ϩ Veh, and mdx ϩ AICAR animals, respectively. There was no difference in the runevoked increase in RIP 140 expression between mdx ϩ Veh and mdx ϩ AICAR animals.
The levels of SIRT1 mRNA were similar across all experimental groups in rest animals (Fig. 5D) . Running augmented SIRT1 gene expression by 1.9-, 4.4-, and 2.7-fold (P Ͻ 0.05) in the WT ϩ Veh, mdx ϩ Veh, and mdx ϩ AICAR mice, respectively. Chronic AICAR administration exhibited a tendency (P ϭ 0.08) to attenuate the running-elicited increase observed in mdx mice; however, this phenomenon of attenuated activation in the mdx ϩ AICAR group compared with the mdx ϩ Veh animals did not attain statistical significance.
Protein arginine methyltransferase expression in mdx mice. We examined the mRNA and protein expression of myogenic regulators PRMT1 and CARM1 (16, 19, 27, 31, 41) , protein arginine methyltransferases (PRMTs) that include PGC-1␣ and RIP 140 among their targets for posttranslational modification (48, 66) . Compared with the WT ϩ Veh rest group, PRMT1 mRNA expression was 1.8-to 2.5-fold greater (P Ͻ 0.05) in the mdx ϩ Veh rest and mdx ϩ AICAR rest groups, respectively (Fig. 6A) . The acute running stimulus augmented PRMT1 levels 1.8-and 4.1-fold (P Ͻ 0.05) in WT ϩ Veh and mdx ϩ Veh animals, respectively. This running-evoked eleva- tion in mdx mice was significantly attenuated (P Ͻ 0.05) after chronic AICAR administration. PRMT1 mRNA content was only 2.4-fold greater (P Ͻ 0.05) in the mdx ϩ AICAR run animals compared with the mdx ϩ AICAR rest mice.
The basal level of skeletal muscle CARM1 mRNA expression was similar across all experimental groups (Fig. 6B) . The running stimulus augmented CARM1 expression by 2.8-and 2-fold (P Ͻ 0.05) in the mdx ϩ Veh and mdx ϩ AICAR groups, respectively. This running-elicited increase tended to be blunted (P ϭ 0.08) in the mdx ϩ AICAR compared with the mdx ϩ Veh animals; however, this was not statistically significant. Thus the acute stress-induced mRNA expression of phenotypic modifiers was attenuated (i.e., PPAR␦, PGC-1␣, PRMT1), or exhibited a strong tendency for an attenuation (i.e., SIRT1, CARM1), downstream of blunted AMPK and p38 signaling subsequent to chronic AICAR administration.
PRMT protein expression and activity have been detailed in myogenic cell cultures (16, 19, 27, 31, 41) . However, to our knowledge, PRMT protein content in skeletal muscle tissue in vivo remains to be examined. Thus, in an effort to further increase our understanding of PRMT biology in skeletal muscle, we examined the protein expression levels of PRMT1 and CARM1 in TA muscle extracts from mdx animals. The PRMT1 and CARM1 contents were not different in response to an acute bout of contractile activity (i.e., rest vs. run; data not shown); therefore, the samples in these treatments were pooled for the analysis comparing experimental groups. PRMT1 content was 40% greater (P Ͻ 0.05) in skeletal muscle of mdx mice compared with their WT littermates (Fig. 7, A and B) . Chronic pharmacological AMPK stimulation had no effect on PRMT1 levels. CARM1 protein content was also significantly higher (ϩ1.3-fold) in dystrophic skeletal muscle compared with muscle from WT animals (Fig. 7, A and C) . AICAR Fig. 7 . Protein expression levels of PRMTs in dystrophic skeletal muscle. A: representative Western blots of PRMT1, CARM1, and GAPDH and a Ponceau S stain from TA muscle extracts of WT ϩ Veh, mdx ϩ Veh, and mdx ϩ AICAR mice. Data for PRMT1 (B) and CARM1 content (C) are expressed as the fold change relative to the levels in WT ϩ Veh mice (n ϭ 12). #P Ͻ 0.05 vs. WT ϩ Veh. *P Ͻ 0.05 vs. mdx ϩ Veh. treatment resulted in a ϳ20% reduction (P Ͻ 0.05) in CARM1 expression in mdx mice.
DISCUSSION
In the present study, we examined the intracellular signaling and gene expression responses in the skeletal muscle of AICARadapted animals subsequent to a complementary physiological stimulus. Dystrophic muscle exposed to chronic AICAR-induced AMPK activation displayed attenuated AMPK and p38 signaling in response to a subsequent acute stress stimulus. Downstream mRNA expression of established phenotypic modifiers, including PPAR␦, PGC-1␣, and SIRT1, was also blunted in the AICARadapted animals. To our knowledge, ours is also the first investigation of PRMT1 and CARM1 biology in mature skeletal muscle in response to chronic and acute cues for muscle phenotypic plasticity. These results provide important insight into the ability of dystrophic muscle to respond to a physiological stimulus subsequent to a pharmacological intervention, which is relevant for possible clinical applications of AMPK agonists in neuromuscular diseases, such as during chronic administration to DMD patients.
AMPK and p38 signaling is altered in dystrophic skeletal muscle. We first sought to characterize the phosphorylation and expression levels of AMPK and p38. We found unique phosphorylation signatures between AMPK and p38 in dystrophic muscle, with the former being higher and the latter being lower compared with skeletal muscle from WT animals. A reduced level of basal p38 phosphorylation in mdx mouse skeletal muscle has been reported previously (8) , although no difference, as well as an elevated level of p38 phosphorylation, has also been observed between mdx and WT mouse skeletal muscle (34, 35, 53) . Thus it seems basal p38 phosphorylation status in dystrophic skeletal muscle may be partly dependent on the fiber-type composition of the muscle examined, as well as the stage of disease progression (8, 34, 35, 53) .
Our data suggest a differential regulation of AMPK and p38 by a number of possible factors, including upstream kinase activity, phosphatase action, or allosteric stimulation. Indeed, alterations in these variables have been documented in dystrophic muscle previously (20, 36, 62, 69) . In contrast, total AMPK and p38 contents were higher in muscle from mdx mice compared with WT animals. Multiple muscle pathologies, including muscular dystrophy (4, 60) and aging-associated sarcopenia (38, 51, 68) , display an elevation in total kinase content. A greater basal kinase enzyme concentration in dystrophic muscle may represent a compensatory adaptation in an attempt to attain the necessary signaling apparatus to be responsive to local cues, including phenotype-shifting stimuli such as mechanical stress, and intracellular calcium or highenergy phosphate flux. This concept is consistent with findings related to Akt, where augmented expression of the kinase via transgenic technology mitigated myonecrosis and significantly counteracted the dystrophic pathology (4, 55) . The use of genetic approaches to identify the roles of AMPK and p38 in the mdx pathology may also be an effective strategy moving forward.
Acute exercise triggers early adaptive responses in muscular dystrophy. We subjected vehicle-and AICAR-treated mice to an acute stress stimulus to assess the AMPK and p38 signaling response. Treadmill running was chosen as the modality to examine kinase signaling for two reasons. First, it is established that contractile activity stimulates AMPK and p38 signaling in the active myofibers (24, 37, 39, 52, 74) . Second, we wanted to contribute to the discussion regarding the suitability of exercise in muscular dystrophy. Our data, discussed below, suggest that exercise can increase the expression of potent phenotype-shifting molecules in dystrophic muscle. If these acute increases in gene expression associated with each bout of activity are repeated over time, via chronic exercise under the auspices of informed exercise prescription, it may prove beneficial in successfully remodeling the active skeletal muscle to be more resistant to the dystrophic pathology. Clearly, more research, in the form of elegantly designed preclinical and clinical studies, is necessary to address the place of exercise in the lives of DMD patients and their families (12, 42) .
The AICAR-elicited activation of the slow, oxidative myogenic program in mdx animals blunts further adaptive AMPK and p38 signaling. In response to running, skeletal muscle AMPK and p38 phosphorylation was augmented. However, in the mdx animals that received the chronic AICAR treatment, the running-elicited signaling induction was attenuated, particularly with respect to AMPK, which was not activated. Consistent with these findings, it was demonstrated previously that AMPK activation via chronic (i.e., 10 days) AICAR administration in healthy animals blunted AMPK and acetyl-CoA carboxylase (ACC) phosphorylation in response to a subsequent bout of acute exercise (43) . Our observations may be due, in part, to the reduced activation of upstream kinases of AMPK and p38. Moreover, in the case of AMPK, this could occur via a lesser production of activating metabolites or, conversely, an increased presence of inhibitory molecules, in the adapted muscle. For example, it has been shown that chronic (i.e., 28 days) AICAR treatment results in an increase in muscle ATP content (3, 75) , and it is known that ATP antagonizes the binding of AMP to the ␥-subunit of AMPK (76) . Thus a decrease in the ratio of AMP to ATP would favor ATP binding to the Bateman domains and a decrease in AMPK activity (76) . Our results suggest that the heightened level of this allosteric inhibitor in the AICAR-adapted muscle may also influence AMPK phosphorylation during contractile activity. It is also possible that AICAR treatment increases protein phosphatase (PP) activity and/or expression and that this results in lower levels of kinase phosphorylation during exercise due to greater protein dephosphorylation. In support of this assertion, metformin, another pharmacological AMPK agonist (49) , induces PP2A activity (29) , and PP2A has been shown to inhibit AMPK (71) and p38 (23) . Thus it is likely that multiple factors are responsible for the tachyphylactic kinase response in AICAR-adapted dystrophic muscle. Nonetheless, our data further support the concept (39, 43, 52) that muscle phenotype represents a salient determinant in the extent of kinase activation important for skeletal muscle plasticity.
Chronic AICAR treatment and acute exercise interact to influence expression of potent phenotypic modifiers in dystrophic muscle. AMPK and p38 participate in the activation of genes important for phenotypic plasticity in skeletal muscle (37) . We examined the mRNA content of PGC-1␣, SIRT1, and PPAR␦, factors known to interact or to be downstream of AMPK and/or p38 (1, 30, 40, 64, 65) , as well as the expression of RIP 140. These data yielded two important results. First, in mdx mouse skeletal muscle, a single bout of treadmill running induced PGC-1␣, SIRT1, and PPAR␦ mRNAs, three molecules that promote the slow, oxidative myogenic program (21, 37, 70) . This phenotype has proven to be more resistant to the dystrophic pathology in DMD patients and mdx animals (13, 14, 26, 40, 45, 47, 63, 72) . These findings indicate that exercise may be beneficial for muscular dystrophy, in part, by upregulating PGC-1␣, SIRT1, and PPAR␦ expression. Since the protein levels of these molecules are already elevated in dystrophic muscle (40, 45) , possibly in an effort to minimize the pathology, further increases in these activators of the slow, oxidative myogenic program may aid in mitigating the disease.
The second key result from these data is that, similar to the attenuation of AMPK and p38 signaling in the AICAR-adapted dystrophic muscle, acute stress-evoked mRNA expression of a suite of phenotypic modifiers, including PPAR␦, PGC-1␣, SIRT1, PRMT1, and CARM1, was also blunted by prior chronic pharmacological AMPK stimulation. This indicates that promotion of the slow, oxidative myogenic program in mdx animals, which is proven to be beneficial for the dystrophic phenotype (13, 14, 26, 40, 45, 47, 63, 72) , mitigates the successive gene expression of phenotypic modifiers. Our data focus on an AICAR-AMPK axis, also potentially including p38, in dystrophic muscle that becomes less sensitive to a complimentary mode of AMPK and p38 stimulation. Further research is necessary to identify whether attenuated plasticity in dystrophic muscle occurs in other adaptive signaling cascades.
Dystrophic skeletal muscle exhibits dynamic PRMT expression in response to acute and chronic stressors. Little has been detailed regarding PRMT content and activity in mature muscle, which is surprising since protein methylation in skeletal muscle was first described ϳ40 yr ago (33) . Protein methylation, primarily 3-methylhistidine of noncollagen proteins (e.g., actin and myosin), is altered in dystrophic skeletal muscle (46, 50) . Protein arginine methylation has been shown to affect the myogenic program in cell culture (16, 27, 31) , whereas PGC-1␣ and RIP 140 activity are directly influenced by arginine methylation in nonmuscle cells (48, 66) . In an effort to shed more light on this system of posttranslational modification in mature skeletal muscle, we 1) assessed PRMT1 and CARM1 mRNA content in response to chronic and acute physiologic perturbations and 2) evaluated the protein expression levels of these factors in WT and mdx mouse muscle. Our data represent the first account that contractile activity induces PRMT expression in mature skeletal muscle. The data also show that PRMT1 and CARM1 protein expression is elevated in dystrophic muscle. Other powerful phenotypic modifiers, including PPAR␦, PGC-1␣, and SIRT1, are also expressed to a greater extent in mdx mouse skeletal muscle (40, 45) , which points to an adaptive strategy employed in dystrophic muscle to upregulate factors that are associated with a phenotype more resistant to the disease pathology.
PRMTs are known to influence the myogenic program in cell culture, for example, through expression and stimulation of myogenic regulatory factors (16, 19) and posttranslational modification of lamin A/C during differentiation (31) . Thus it is reasonable to suggest that PRMT induction in response to downhill running may be mediating part of a muscle degeneration/regeneration program in mdx animals. Notably, in WT mice, PRMT1 and CARM1 induction occurred to a lesser extent compared with that observed in dystrophic animals, indicative of a potentially lower regenerative response subsequent to the running stimulus compared with the mdx mice. Therefore, the elevated expression of PRMTs in dystrophic muscle may be explained by two phenomena: 1) in mature myofibers, as a compensatory upregulation to potentially mediate the phenotype-shifting abilities of PGC-1␣ and RIP 140 (48, 66) toward the slow, oxidative myogenic program, and 2) in regenerating fibers, to facilitate myogenesis and muscle repair.
In summary, our data show that chronically AICAR-treated mdx animals displayed attenuated AMPK and p38 signaling in skeletal muscle in response to a subsequent complementary acute stress stimulus. Moreover, PPAR␦, PGC-1␣, SIRT1, PRMT1, and CARM1 messages were also blunted in the AICAR-adapted animals. Our results provide further insight into the ability of dystrophic muscle to adapt over time to a contextually novel pharmacological intervention, which is relevant for potential future therapeutic applications of synthetic agonists in neuromuscular diseases, such as during chronic administration to DMD patients.
